1 Min Read
Nov 14 (Reuters) - Astrazeneca Plc
* FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.